Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11199747 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| SCHEMBL11200026 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| SCHEMBL2104647 | 0.81 | — | — | |
| SCHEMBL469045 | 0.78 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1MAPTGAALMNA | |
| SCHEMBL12409575 | 0.78 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1MAPTGAALMNA | |
| SCHEMBL11817502 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| SCHEMBL11812131 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| SCHEMBL5111267 | 0.78 | MITF (0.50) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| Hydrochloric Acid SCHEMBL11200108 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTGAAMITF | |
| Hydrochloric Acid SCHEMBL21879630 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | SMN1; SMN2 2527/4885ALDH1A1 2177/4885MAPT 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.